Pfizer, Merck KGaA’s Bavencio flunks study in hard-to-treat gastric cancer

The PD-L1 inhibitor Bavencio did not outperform chemo at extending patients’ lives in a major study in gastric cancer, raising questions about the usefulness of immuno-oncology drugs in fighting the disease.